. 2016 Apr; 143(2):135-44.
doi: 10.4103/0971-5916.180197.

Immune based therapy for melanoma

Robert Ancuceanu 1 Monica Neagu  
  • PMID: 27121512
  •     65 References
  •     10 citations


A few years ago therapeutic options in advanced melanoma were very limited and the prognosis was somber. Although recent progresses are far from providing a cure for advanced melanoma, yet these have kindled new hopes and searching for a cure does not seem unreasonable. Seven new medicines have been authorized in various regions of the world in the recent past in the therapy of advanced melanoma, over half of them acting by mechanisms involving the immune system of the host. The anti-CTLA-4 (cytotoxic T lymphocyte associated protein-4) ipilimumab has been followed by anti-PD1 (programmed death1) inhibitors, more effective and safer. Very recently, the first oncolytic immunotherapy, talimogene laherparepvec (T-VEC) has been authorized for placing on the market and a variety of combinations of the new therapies are currently being evaluated or considered. Besides, a plethora of other molecules and approaches, especially monoclonal antibodies, are in the preliminary phases of clinical investigation and are likely to bring new benefits for the treatment of this potentially fatal form of cancer.

Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Bettina Weigelin, Elixabet Bolaños, +10 authors, Ignacio Melero.
Proc Natl Acad Sci U S A, 2015 Jun 03; 112(24). PMID: 26034288    Free PMC article.
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Geoffrey T Gibney, Ragini R Kudchadkar, +13 authors, Jeffrey S Weber.
Clin Cancer Res, 2014 Dec 20; 21(4). PMID: 25524312    Free PMC article.
Highly Cited.
Cancer immunoediting: from immunosurveillance to tumor escape.
Gavin P Dunn, Allen T Bruce, +2 authors, Robert D Schreiber.
Nat Immunol, 2002 Oct 31; 3(11). PMID: 12407406
Highly Cited. Review.
Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma.
Ying Li, Jiani Yuan, +6 authors, Siwang Wang.
Int J Nanomedicine, 2014 Dec 17; 9. PMID: 25506218    Free PMC article.
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
Miguel F Sanmamed, Inmaculada Rodriguez, +14 authors, Ignacio Melero.
Cancer Res, 2015 Jun 27; 75(17). PMID: 26113085
Update on immune checkpoint inhibitors in lung cancer.
Benjamin C Creelan.
Cancer Control, 2013 Dec 21; 21(1). PMID: 24357746
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Paolo A Ascierto, Michael Atkins, +34 authors, Magdalena Thurin.
J Transl Med, 2015 Dec 02; 13. PMID: 26619946    Free PMC article.
Reply to K.S. Wilson et al.
Antoni Ribas, Axel Hauschild, Richard Kefford.
J Clin Oncol, 2013 Sep 24; 31(22). PMID: 24058931
Immune Checkpoint Inhibitors.
John B A G Haanen, Caroline Robert.
Prog Tumor Res, 2015 Sep 19; 42. PMID: 26382943
New developments in the management of advanced melanoma - role of pembrolizumab.
Giuseppina Improta, Isabella Leone, +3 authors, Filippo Fraggetta.
Onco Targets Ther, 2015 Sep 24; 8. PMID: 26396529    Free PMC article.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Caroline Robert, Antoni Ribas, +22 authors, Adil Daud.
Lancet, 2014 Jul 19; 384(9948). PMID: 25034862
Highly Cited.
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.
Lucy S K Walker, David M Sansom.
Nat Rev Immunol, 2011 Nov 26; 11(12). PMID: 22116087
Highly Cited.
Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?
Gérald E Piérard, François Aubin, Philippe Humbert.
Dermatol Res Pract, 2011 Nov 03; 2012. PMID: 22046181    Free PMC article.
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
Muhammad Khattak, Rosalie Fisher, Samra Turajlic, James Larkin.
Ther Adv Med Oncol, 2013 Mar 02; 5(2). PMID: 23450149    Free PMC article.
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.
David L Bajor, Xiaowei Xu, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2014 Sep 26; 2(11). PMID: 25252722    Free PMC article.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.
Raju R Raval, Andrew B Sharabi, +2 authors, Padmanee Sharma.
J Immunother Cancer, 2014 Jun 03; 2. PMID: 24883190    Free PMC article.
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Luis H Camacho.
Cancer Med, 2015 Jan 27; 4(5). PMID: 25619164    Free PMC article.
The immunobiology of cancer immunosurveillance and immunoediting.
Gavin P Dunn, Lloyd J Old, Robert D Schreiber.
Immunity, 2004 Aug 17; 21(2). PMID: 15308095
Highly Cited. Review.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Elizabeth I Buchbinder, Anupam Desai.
Am J Clin Oncol, 2015 Nov 13; 39(1). PMID: 26558876    Free PMC article.
Highly Cited. Review.
Emerging immune checkpoints for cancer therapy.
Xiaodong Li, Wenwei Hu, +8 authors, Changping Wu.
Acta Oncol, 2015 Sep 12; 54(10). PMID: 26361073
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lei Lu, Xiaobing Xu, +3 authors, Xuan Wang.
J Transl Med, 2014 Feb 08; 12. PMID: 24502656    Free PMC article.
Hepatotoxicity with combination of vemurafenib and ipilimumab.
Antoni Ribas, F Stephen Hodi, +2 authors, Jedd Wolchok.
N Engl J Med, 2013 Apr 05; 368(14). PMID: 23550685
Highly Cited.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
Update on the Epidemiology of Melanoma.
Steven T Chen, Alan C Geller, Hensin Tsao.
Curr Dermatol Rep, 2013 Apr 13; 2(1). PMID: 23580930    Free PMC article.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
IMMUNOLOGY. Moving CTLA-4 from the trash to recycling.
David M Sansom.
Science, 2015 Jul 25; 349(6246). PMID: 26206917
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, +25 authors, Paolo A Ascierto.
N Engl J Med, 2014 Nov 18; 372(4). PMID: 25399552
Highly Cited.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Robert H I Andtbacka, Howard L Kaufman, +26 authors, Robert S Coffin.
J Clin Oncol, 2015 May 28; 33(25). PMID: 26014293
Highly Cited.
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Ivan Márquez-Rodas, Pablo Cerezuela, +4 authors, Salvador Martín-Algarra.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605313    Free PMC article.
Melanoma: oncogenic drivers and the immune system.
Niki Karachaliou, Sara Pilotto, +10 authors, Rafael Rosell.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605311    Free PMC article.
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F Stephen Hodi, Sandra Lee, +7 authors, John M Kirkwood.
JAMA, 2014 Nov 05; 312(17). PMID: 25369488    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
The immune system--a hidden treasure for biomarker discovery in cutaneous melanoma.
Monica Neagu.
Adv Clin Chem, 2012 Sep 07; 58. PMID: 22950344
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Emanuela Romano, Olivier Michielin, +8 authors, Alexandre Harari.
J Transl Med, 2014 Apr 15; 12. PMID: 24726012    Free PMC article.
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.
L M Muul, P J Spiess, E P Director, S A Rosenberg.
J Immunol, 1987 Feb 01; 138(3). PMID: 3100623
Highly Cited.
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
Ahmad A Tarhini, Haris Zahoor, +6 authors, John M Kirkwood.
J Transl Med, 2015 Oct 01; 13. PMID: 26419843    Free PMC article.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, +20 authors, KEYNOTE-006 investigators.
N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173
Highly Cited.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
Chrystal M Paulos, Carl H June.
J Clin Invest, 2009 Dec 30; 120(1). PMID: 20038807    Free PMC article.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, +25 authors, James Larkin.
Lancet Oncol, 2015 Mar 22; 16(4). PMID: 25795410
Highly Cited.
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Jeffrey S Weber, Ragini Reiney Kudchadkar, +11 authors, Y Ann Chen.
J Clin Oncol, 2013 Oct 23; 31(34). PMID: 24145345    Free PMC article.
Highly Cited.
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.
Shin Foong Ngiow, Bianca von Scheidt, +3 authors, Mark J Smyth.
Cancer Res, 2011 Mar 25; 71(10). PMID: 21430066
Highly Cited.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Antoni Ribas, Igor Puzanov, +33 authors, Adil Daud.
Lancet Oncol, 2015 Jun 28; 16(8). PMID: 26115796    Free PMC article.
Highly Cited.
Immuno-regulatory antibodies for the treatment of cancer.
Jamie Honeychurch, Eleanor J Cheadle, Simon J Dovedi, Timothy M Illidge.
Expert Opin Biol Ther, 2015 Apr 18; 15(6). PMID: 25882106
Rationale for anti-OX40 cancer immunotherapy.
Sandrine Aspeslagh, Sophie Postel-Vinay, +3 authors, Aurélien Marabelle.
Eur J Cancer, 2015 Dec 10; 52. PMID: 26645943
Highly Cited. Review.
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
Sven de Vos, Andres Forero-Torres, +10 authors, Ranjana Advani.
J Hematol Oncol, 2014 Jun 13; 7. PMID: 24919462    Free PMC article.
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Antoni Ribas, Luis H Camacho, +10 authors, Jesus Gomez-Navarro.
J Clin Oncol, 2005 Oct 06; 23(35). PMID: 16204013
Highly Cited.
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Alexander M M Eggermont, Vanna Chiarion-Sileni, +19 authors, Alessandro Testori.
Lancet Oncol, 2015 Apr 05; 16(5). PMID: 25840693
Highly Cited.
What's new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola, Michael B Atkins.
J Transl Med, 2015 Jul 05; 13. PMID: 26141621    Free PMC article.
Incidence of cutaneous malignant melanoma by socioeconomic status in Canada: 1992-2006.
Stephanie E Johnson-Obaseki, Varant Labajian, Martin J Corsten, James T McDonald.
J Otolaryngol Head Neck Surg, 2015 Dec 04; 44. PMID: 26631308    Free PMC article.
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Taku Okazaki, Shunsuke Chikuma, +2 authors, Tasuku Honjo.
Nat Immunol, 2013 Nov 19; 14(12). PMID: 24240160
Highly Cited. Review.
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
S Jang, M B Atkins.
Clin Pharmacol Ther, 2013 Oct 02; 95(1). PMID: 24080641
Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
Trevor McKibbin.
Am J Manag Care, 2015 Dec 01; 21(10 Suppl). PMID: 26619296
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
David A Schaer, Sadna Budhu, +8 authors, Jedd D Wolchok.
Cancer Immunol Res, 2014 Jan 15; 1(5). PMID: 24416730    Free PMC article.
Highly Cited.
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Holbrook E Kohrt, Ariane Thielens, +14 authors, Pascale André.
Blood, 2013 Dec 12; 123(5). PMID: 24326534    Free PMC article.
Highly Cited.
How should we use anti-CTLA-4 antibodies?
Aurélien Marabelle, Alexander Eggermont.
Eur J Cancer, 2015 Nov 29; 51(17). PMID: 26613660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Immunotherapy for advanced melanoma: fulfilling the promise.
Helen Gogas, Aristidis Polyzos, John Kirkwood.
Cancer Treat Rev, 2013 Jun 04; 39(8). PMID: 23725878
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, +32 authors, Luis A Diaz.
N Engl J Med, 2015 Jun 02; 372(26). PMID: 26028255    Free PMC article.
Highly Cited.
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
Deepak Mittal, Matthew M Gubin, Robert D Schreiber, Mark J Smyth.
Curr Opin Immunol, 2014 Feb 18; 27. PMID: 24531241    Free PMC article.
Highly Cited. Review.
VISTA is an immune checkpoint molecule for human T cells.
J Louise Lines, Eirini Pantazi, +8 authors, Randolph Noelle.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691993    Free PMC article.
Highly Cited.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Donald Lawrence, +20 authors, David McDermott.
Cancer Immunol Res, 2014 May 20; 2(7). PMID: 24838938    Free PMC article.
Highly Cited.
PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
Zhijuan Lin, Xing Chen, +4 authors, Mingzhe Han.
PLoS One, 2016 Aug 03; 11(8). PMID: 27483468    Free PMC article.
Systematic Review.
Extracellular protonation modulates cell-cell interaction mechanics and tissue invasion in human melanoma cells.
Verena Hofschröer, Alexander Koch, +4 authors, Albrecht Schwab.
Sci Rep, 2017 Feb 17; 7. PMID: 28205573    Free PMC article.
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments.
Cristina Vajaitu, Carmen Cristina Draghici, +6 authors, Vlad Mihai Voiculescu.
J Immunol Res, 2018 Nov 13; 2018. PMID: 30417020    Free PMC article.
miRNAs in the Diagnosis and Prognosis of Skin Cancer.
Monica Neagu, Carolina Constantin, Sanda Maria Cretoiu, Sabina Zurac.
Front Cell Dev Biol, 2020 Mar 19; 8. PMID: 32185171    Free PMC article.
IgY - turning the page toward passive immunization in COVID-19 infection (Review).
Carolina Constantin, Monica Neagu, +2 authors, Demetrios A Spandidos.
Exp Ther Med, 2020 Jun 17; 20(1). PMID: 32536989    Free PMC article.
Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma.
Corina Daniela Ene, Mircea Tampa, +6 authors, Simona Roxana Georgescu.
J Immunol Res, 2020 Aug 29; 2020. PMID: 32855975    Free PMC article.
Inflammation: A key process in skin tumorigenesis.
Monica Neagu, Carolina Constantin, +3 authors, Sabina Zurac.
Oncol Lett, 2019 Apr 05; 17(5). PMID: 30944600    Free PMC article.
Highly Cited. Review.
Tumor infiltrating lymphocytes: The regulator of melanoma evolution.
Mihaela Antohe, Roxana Ioana Nedelcu, +12 authors, Gabriela Turcu.
Oncol Lett, 2019 Apr 05; 17(5). PMID: 30944610    Free PMC article.
Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors.
George Tzanakakis, Eirini-Maria Giatagana, +4 authors, Dragana Nikitovic.
Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32847060    Free PMC article.
Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.
Aikaterini Berdiaki, Monica Neagu, +4 authors, Dragana Nikitovic.
Biomolecules, 2021 Apr 04; 11(3). PMID: 33800172    Free PMC article.